Immune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations.
Dagogo-Jack I, Mitchell O, Codd E, Li A, Mitchell D, Flynn SE, Sivamanoharan N, Reeves P, Poznansky M, Valiev I, Kosmin A, Yeap BY, Hambelton G, Iafrate AJ, Lennerz JK, Hung YP, Kindler H.
Dagogo-Jack I, et al. Among authors: li a.
J Thorac Oncol. 2025 Jun 25:S1556-0864(25)00806-8. doi: 10.1016/j.jtho.2025.06.018. Online ahead of print.
J Thorac Oncol. 2025.
PMID: 40578509